Adding a high dose of erythropoietin to therapeutic hypothermia did not reduce rates of death or disability in infants with neonatal hypoxic ischemic encephalopathy (HIE), a phase III randomized trial ...
Hypoxic-ischemic encephalopathy (HIE) is one of the leading causes of newborn mortality and morbidity worldwide, and lowering the baby’s body temperature—called therapeutic hypothermia—is often used ...
Erythropoietin, a treatment for newborns with critically low levels of oxygen or blood supply to the brain at birth, does not prevent death or disability, according to a new multinational study. The ...
Researchers at UHealth-;the University of Miami Health System and the University of Miami Miller School of Medicine have shown that, in two cases, COVID-19 infection breached the placenta and caused ...
ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute ...
Erythropoietin, a treatment for newborns with critically low levels of oxygen or blood supply to the brain at birth, does not prevent death or disability, according to a new multinational study. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback